News H. Lundbeck A/S

Equities

HLUN B

DK0061804770

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 12:35:26 17/04/2026 BST			5-day change	1st Jan Change
42.27 ^DKK	+1.27%		+4.41%	-2.32%

04-13	Lundbeck to present new neurology data at upcoming congress	FW
03-23	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth	MT

All News

04-13	Lundbeck to present new neurology data at upcoming congress	FW
04-13	Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting	AQ
03-30	H Lundbeck A/S : Remuneration Policy 2026 (Remuneration Policy 2026)	PU
03-23	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth	MT
03-20	H Lundbeck: Markets need more proof of growth promise
03-18	H. Lundbeck A/S Announces Board and Board Committee Appointments	CI
03-18	H. Lundbeck A/S Approves Dividend for the Accounting Year 2025	CI
03-18	Lundbeck held its Annual General Meeting on 18 March 2026 at the company's registered office	AQ
03-18	H Lundbeck A/S : Presentation (AGM Presentation 2026)	PU
03-18	H. Lundbeck A/S - Shareholder/Analyst Call
03-16	H. Lundbeck A/S Advances Parkinson's Research With New Phase 1b Data On Lu AF28996 And Presents Updates On Multiple System Atrophy Programs	CI
03-16	Lundbeck presents new Phase 1b Parkinson's data	FW
03-16	Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026	AQ
03-10	H. Lundbeck A/S Appoints Markus Kede as Senior Vice President and Chief AI Officer and Joins Executive Leadership Team, Effective July 1, 2026	CI
03-10	H. Lundbeck Names Chief Artificial Intelligence Officer	MT
03-10	Lundbeck appoints Head of AI	FW
03-10	Lundbeck appoints Chief AI Officer	AQ
03-09	H. Lundbeck Randomizes Last Patient in Late-stage Trial for Amlenetug	MT
03-09	Lundbeck completes recruitment for Phase 3 MSA study	FW
03-09	Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial	AQ
03-09	H. Lundbeck A/S Announces Last Patient Randomized in Phase 3 Mascot Trial	CI
03-05	Nordea Resumes Coverage of Lundbeck With Buy Rating – Too Cheap to Ignore	FW
03-05	Nordea Resumes Coverage of Lundbeck with Buy Rating and Price Target of 55 Danish Kroner	FW
03-02	Jefferies Upgrades Lundbeck to Hold (Underperform), Sets Price Target at 39 Danish Kroner	FW
02-17	Deutsche Bank Lowers Price Target for Lundbeck to 40 Danish Kroner (44), Maintains Hold Recommendation	FW